TLDR
CAPA stands for Corrective and Preventive Action. It is a formal, systematic quality management process that identifies the root causes of quality problems, implements verified fixes, and documents every step so regulators can confirm the system worked. CAPA is required under FDA 21 CFR Part 820.100 (QMSR), ISO 13485 Clauses 8.5.2 and 8.5.3, and ICH Q10. CAPA deficiencies rank consistently in the top five FDA Form 483 observations across all regulated industries.
What Is CAPA?
CAPA stands for Corrective and Preventive Action. In regulated industries, it refers to a structured system for identifying, investigating, and resolving quality problems in a way that prevents them from recurring.
Every quality management system in a regulated environment will have nonconformances, deviations, complaints, audit findings, and manufacturing failures. CAPA is how those events get resolved properly — not just closed on paper, but genuinely fixed at the source and verified.
The two components address different problems:
- Corrective Action: An action taken to eliminate the root cause of a confirmed nonconformity or quality failure, to prevent its recurrence.
- Preventive Action: An action taken to eliminate the cause of a potential nonconformity or quality risk, to prevent its occurrence before it happens.
The distinction matters: corrective action responds to something that already happened; preventive action addresses something that presents a future risk. Both are regulatory requirements, and both belong in a compliant quality management system.
Corrective Action vs. Preventive Action: The Critical Difference
Many quality teams treat CAPA as one unified process, but FDA and ISO 13485 treat corrective and preventive action as separate clauses with different triggers and expectations.
Corrective action is triggered by an actual nonconformance: a deviation, an out-of-specification result, a customer complaint, an audit finding, or any confirmed quality failure. The goal is to identify the root cause and eliminate it so the same problem does not recur.
Preventive action is triggered by risk signals: trending data that suggests a problem may occur, a risk assessment that identifies a gap, or an observation that could become a nonconformance if left unaddressed. The goal is to act before the failure occurs.
This distinction creates a practical challenge in many regulated companies. Corrective action is well-understood because it follows a clear trigger. Preventive action is less consistently executed because it requires proactive analysis of quality data — something that many teams lack the systems or bandwidth to perform reliably.
Under FDA QMSR, this expectation is explicit: organizations must analyze sources of quality data to identify and eliminate potential nonconformances before they occur.
CAPA Regulatory Requirements
FDA 21 CFR Part 820 / QMSR
FDA's Quality Management System Regulation (QMSR), effective February 2026, aligns 21 CFR Part 820 with ISO 13485:2016. The core CAPA requirement is in 21 CFR Part 820.100, which requires medical device manufacturers to:
- Analyze processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product or other quality problems
- Investigate the cause of nonconformities relating to product, processes, and the quality system
- Identify the action needed to correct and prevent recurrence of nonconforming product and other quality problems
- Verify or validate the corrective and preventive action taken to ensure effectiveness and no adverse effect on finished devices
- Implement and document changes in methods and procedures needed to correct and prevent identified quality problems
- Disseminate information related to quality problems or nonconforming product to those directly responsible
FDA investigators conduct CAPA subsystem reviews in virtually every inspection. An investigator will trace a nonconformance from detection through root cause analysis, corrective action implementation, and effectiveness verification. Gaps at any step are a direct path to a 483 observation.
ISO 13485:2016 Clauses 8.5.2 and 8.5.3
ISO 13485:2016 addresses corrective action and preventive action in separate clauses.
Clause 8.5.2 (Corrective Action) requires organizations to take action to eliminate the causes of nonconformities to prevent recurrence, proportionate to the effects of the nonconformities encountered. Required outputs include a review of nonconformities (including customer complaints), determination of causes, evaluation of the need for action to prevent recurrence, implementation of corrective action, records of results, and review of corrective action effectiveness.
Clause 8.5.3 (Preventive Action) requires organizations to determine action to eliminate the causes of potential nonconformities to prevent their occurrence, proportionate to the effects of the potential problems.
FDA 21 CFR Part 211 (Pharmaceuticals)
For pharmaceutical manufacturers, CAPA requirements derive from 21 CFR Part 211. While Part 211 does not use the term "CAPA" explicitly, the requirements for investigation of discrepancies (211.192), laboratory controls (211.160), and annual product review (211.180) collectively create the same regulatory expectation: investigate quality failures, identify root causes, implement corrections, and verify effectiveness.
ICH Q10 Pharmaceutical Quality System
ICH Q10 formally defines CAPA as a Pharmaceutical Quality System element. Section 3.2 requires a process to investigate the root cause of deviations, complaints, and trends; a system to proactively identify potential sources of nonconformance; and monitoring of implemented actions to confirm effectiveness.
The CAPA Process: 8 Steps
A compliant CAPA process in a regulated environment follows these eight steps.
1. Event Detection and CAPA Initiation
A nonconformance, deviation, audit finding, complaint, or risk signal triggers a CAPA record. The record captures the source event, the product or process affected, the severity, and the responsible individuals. In a validated eQMS, this initiation step links the CAPA directly to the source record — a deviation CAPA, for example, carries a direct traceable link to the deviation that generated it.
2. Containment
Before root cause analysis begins, the immediate impact of the problem is contained. For a product issue, this means placing affected product on hold or initiating a recall assessment. Containment does not fix the root cause. It limits further exposure while the investigation proceeds.
3. Problem Definition and Scope
The problem is defined precisely: what happened, where it happened, when it happened, and how often it has happened. This scoping step is frequently rushed in organizations with high CAPA volumes — which is exactly why vague problem statements appear so often as a contributing factor in ineffective CAPAs.
4. Root Cause Analysis
Root cause analysis (RCA) is the technical core of the CAPA process. The most common RCA methods in regulated industries include:
- 5 Whys: Iteratively asking “why” until the underlying cause is reached. Effective for simpler problems with clear causal chains.
- Fishbone Diagram (Ishikawa): Maps potential causes across categories — Method, Machine, Material, Man, Measurement, Environment. Effective for complex problems with multiple contributing factors.
- Fault Tree Analysis: A top-down deductive approach that models the paths that lead to a specific failure. Common in medical device and aerospace quality systems.
- Failure Mode and Effects Analysis (FMEA): Identifies potential failure modes and their effects before they occur. Used proactively for preventive action.
A root cause investigation must be documented in sufficient detail to demonstrate to an FDA investigator that the analysis was thorough, systematic, and proportionate to the risk involved.
5. Corrective Action Implementation
Once the root cause is confirmed, corrective actions are defined and implemented. Actions must address the root cause, not just the symptom. If the root cause is a procedure gap, the corrective action must update the procedure, retrain affected personnel, and verify that the updated procedure is followed. If the root cause is an equipment defect, the corrective action must address the equipment and validate the fix.
6. Preventive Action Determination
Beyond fixing what happened, the CAPA process requires consideration of whether the same root cause could produce a similar problem elsewhere. This lateral thinking — "where else could this happen?" — drives preventive actions across other products, processes, sites, or suppliers.
7. Effectiveness Verification
The most consistently cited gap in CAPA systems is the absence of a defined effectiveness check. After corrective actions are implemented, the organization must verify that the actions worked: the problem did not recur, the root cause was genuinely eliminated, and no adverse effects on product or process were introduced.
Effectiveness checks must be planned before closure, with specific measurable criteria, a defined timeframe, and a responsible owner. An effectiveness check that says "monitor ongoing" without measurable criteria will not satisfy an FDA investigator.
8. Closure and Audit Trail
CAPA records must be closed with complete documentation: root cause confirmed, corrective actions implemented and verified, effectiveness check completed, records reviewed and approved by a qualified authority. The audit trail must be electronic, time-stamped, and tamper-evident for any FDA 21 CFR Part 11-regulated system.
Common CAPA Failures at FDA Inspections
CAPA deficiencies rank among the top five FDA 483 observations every year. The most common patterns:
No defined effectiveness check. CAPAs closed without a planned effectiveness verification or with only a generic "monitor for recurrence" statement. Investigators will probe whether the corrective action was actually verified to work — a vague closure will not hold up.
Root cause labeled as operator error. When root cause analysis consistently attributes problems to human error without investigating the underlying system, process, or training deficiencies, it signals a CAPA program that avoids real causes. FDA investigators recognize this pattern immediately.
Overdue CAPAs with no escalation. A CAPA system where open records age past due dates without escalation, management review, or documented justification for extension is a direct observation waiting to happen.
Inadequate scope. Corrective actions that address only the specific occurrence without considering whether the same root cause exists elsewhere in the product line, process, or site.
CAPA not initiated for recurring issues. When the same deviation, nonconformance, or complaint pattern recurs without triggering a CAPA, investigators will question whether the organization has a functional trending and escalation process.
Corrective action does not match root cause. The most fundamental failure: the corrective action addresses the symptom, not the cause identified in the root cause analysis. This results in recurrence — and a repeat 483 observation in the next inspection cycle.
How an eQMS Supports a Compliant CAPA Process
Paper-based and spreadsheet-driven CAPA systems create structural compliance risk. When CAPA records live in email threads, shared drives, or Excel trackers, the audit trail is manually assembled, effectiveness checks are tracked inconsistently, and root cause documentation is often insufficient.
A validated electronic QMS builds the CAPA compliance framework into the workflow itself:
- Source events — deviations, complaints, audit findings, nonconformances — automatically link to CAPA records with full traceability
- Root cause analysis tools are embedded in the investigation workflow
- Corrective action tasks are assigned with due dates and escalation triggers
- Effectiveness checks are required before closure, with configurable criteria and verification steps
- The complete CAPA record carries an electronic, time-stamped audit trail that meets 21 CFR Part 11 requirements
- Trending and analytics surface recurring issues before they become inspection findings
Cloudtheapp's CAPA module runs on a no-code, fully validated platform aligned with FDA QMSR, ISO 13485, and 21 CFR Part 11. Quality teams configure the CAPA workflow to match their specific process requirements without custom coding or lengthy implementation projects. New CAPAs link directly to deviations, supplier quality management events, audit findings, and complaint records, with AI-assisted root cause suggestions based on the organization's own historical quality data.
People Also Ask
What is the difference between a corrective action and a preventive action?
Corrective action responds to a nonconformance that already occurred. It identifies the root cause and eliminates it to prevent recurrence. Preventive action responds to a potential nonconformance that has not yet occurred — it removes risk signals before they become quality failures.
Is CAPA required by FDA?
Yes. CAPA is required under 21 CFR Part 820.100 (QMSR) for medical device manufacturers and expected under 21 CFR Part 211 for pharmaceutical manufacturers. CAPA deficiencies are among the most frequently cited FDA 483 observations.
What is CAPA in ISO 13485?
ISO 13485:2016 addresses corrective action in Clause 8.5.2 and preventive action in Clause 8.5.3. Both require documented investigation, root cause determination, action implementation, and effectiveness verification.
How long should a CAPA take to close?
There is no universal regulatory timeline, but organizations must define their own target closure timeframes and document any extensions with justification. FDA investigators assess whether open CAPAs are actively managed and whether effectiveness checks occur within a reasonable period after corrective action implementation.
What is a CAPA effectiveness check?
An effectiveness check is a planned verification that a corrective action solved the root cause and prevented recurrence. It must be defined before the CAPA is closed, with specific measurable criteria, a defined timeframe, and a responsible owner.
What triggers a CAPA?
CAPAs are typically triggered by deviations, nonconformances, customer complaints, adverse events, audit findings, failed effectiveness checks on previous CAPAs, trend analysis results, or risk assessments. A validated eQMS links source records directly to CAPA initiation automatically.
Conclusion
CAPA is not a form to complete when something goes wrong. It is the mechanism by which a quality management system identifies its own weaknesses, corrects them at the root, and demonstrates to regulators that those corrections actually worked.
Organizations that treat CAPA as a documentation exercise consistently face repeat inspection observations on the same issues. A compliant, effective CAPA process requires a defined workflow, thorough root cause analysis, corrective actions that address causes rather than symptoms, planned effectiveness verification, and a complete audit trail.
For regulated companies managing CAPA at scale, a validated eQMS eliminates the structural compliance risks that paper-based and spreadsheet systems create — and gives quality teams the real-time visibility they need to close CAPAs correctly the first time.
Request a demo at cloudtheapp.com to see the Cloudtheapp CAPA module configured for your specific quality process.